CN1246315C - 氨基烷基苯甲酰基－苯并呋喃或苯并噻吩类，它们的制备方法与含有它们的组合物 - Google Patents

氨基烷基苯甲酰基－苯并呋喃或苯并噻吩类，它们的制备方法与含有它们的组合物 Download PDF

Info

Publication number
CN1246315C
CN1246315C CNB018177670A CN01817767A CN1246315C CN 1246315 C CN1246315 C CN 1246315C CN B018177670 A CNB018177670 A CN B018177670A CN 01817767 A CN01817767 A CN 01817767A CN 1246315 C CN1246315 C CN 1246315C
Authority
CN
China
Prior art keywords
group
formula
compound
cumarone
following general
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018177670A
Other languages
English (en)
Chinese (zh)
Other versions
CN1471521A (zh
Inventor
J·－L·阿森斯
C·伯恩哈特
F·卡巴内尔－豪德里库尔特
P·戈蒂尔
D·尼萨托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN1471521A publication Critical patent/CN1471521A/zh
Application granted granted Critical
Publication of CN1246315C publication Critical patent/CN1246315C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
CNB018177670A 2000-08-23 2001-08-21 氨基烷基苯甲酰基－苯并呋喃或苯并噻吩类，它们的制备方法与含有它们的组合物 Expired - Fee Related CN1246315C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/10834 2000-08-23
FR0010834A FR2813306B1 (fr) 2000-08-23 2000-08-23 Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant

Publications (2)

Publication Number Publication Date
CN1471521A CN1471521A (zh) 2004-01-28
CN1246315C true CN1246315C (zh) 2006-03-22

Family

ID=8853674

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018177670A Expired - Fee Related CN1246315C (zh) 2000-08-23 2001-08-21 氨基烷基苯甲酰基－苯并呋喃或苯并噻吩类，它们的制备方法与含有它们的组合物

Country Status (36)

Country Link
US (1) US6949583B2 (US06949583-20050927-C00024.png)
EP (1) EP1315709B1 (US06949583-20050927-C00024.png)
JP (2) JP5081363B2 (US06949583-20050927-C00024.png)
KR (1) KR100911280B1 (US06949583-20050927-C00024.png)
CN (1) CN1246315C (US06949583-20050927-C00024.png)
AR (1) AR032892A1 (US06949583-20050927-C00024.png)
AT (1) ATE469138T1 (US06949583-20050927-C00024.png)
AU (2) AU2001284149B2 (US06949583-20050927-C00024.png)
BG (1) BG66240B1 (US06949583-20050927-C00024.png)
BR (1) BR0113425B1 (US06949583-20050927-C00024.png)
CA (1) CA2415847C (US06949583-20050927-C00024.png)
CY (1) CY1110738T1 (US06949583-20050927-C00024.png)
CZ (1) CZ304003B6 (US06949583-20050927-C00024.png)
DE (1) DE60142240D1 (US06949583-20050927-C00024.png)
DK (1) DK1315709T3 (US06949583-20050927-C00024.png)
EA (1) EA006237B1 (US06949583-20050927-C00024.png)
ES (1) ES2346291T3 (US06949583-20050927-C00024.png)
FR (1) FR2813306B1 (US06949583-20050927-C00024.png)
HK (1) HK1053113A1 (US06949583-20050927-C00024.png)
HU (1) HU229456B1 (US06949583-20050927-C00024.png)
IL (2) IL153632A0 (US06949583-20050927-C00024.png)
IS (1) IS2821B (US06949583-20050927-C00024.png)
MA (1) MA26943A1 (US06949583-20050927-C00024.png)
ME (2) MEP23008A (US06949583-20050927-C00024.png)
MX (1) MXPA03001463A (US06949583-20050927-C00024.png)
NO (1) NO328138B1 (US06949583-20050927-C00024.png)
NZ (1) NZ523446A (US06949583-20050927-C00024.png)
OA (1) OA12359A (US06949583-20050927-C00024.png)
PL (1) PL219848B1 (US06949583-20050927-C00024.png)
PT (1) PT1315709E (US06949583-20050927-C00024.png)
RS (1) RS51603B (US06949583-20050927-C00024.png)
SI (1) SI1315709T1 (US06949583-20050927-C00024.png)
SK (1) SK288126B6 (US06949583-20050927-C00024.png)
TW (1) TWI290920B (US06949583-20050927-C00024.png)
WO (1) WO2002016339A1 (US06949583-20050927-C00024.png)
ZA (1) ZA200300744B (US06949583-20050927-C00024.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7401072B2 (en) * 2003-06-10 2008-07-15 Google Inc. Named URL entry
RU2409352C2 (ru) * 2005-05-05 2011-01-20 САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи Стабильные составы наночастиц
FR2893616B1 (fr) * 2005-11-23 2008-01-04 Sanofi Aventis Sa Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
EP2308488A1 (en) 2009-10-09 2011-04-13 Sanofi-Aventis Use of celivarone for the preparation of a medicament for use in the prevention of implantable cardioverter defibrillator interventions or death
US20110207811A1 (en) * 2010-02-19 2011-08-25 Sanofi-Aventis Use of celivarone for reducing occurrences of cardiovascular hospitalization
FR2958290B1 (fr) 2010-03-30 2012-10-19 Sanofi Aventis Procede de preparation de derives de sulfonamido-benzofurane
HUP1000330A2 (en) 2010-06-18 2011-12-28 Sanofi Sa Process for the preparation of dronedarone and the novel intermediates
AU2011202542A1 (en) 2010-07-14 2012-02-02 Indian Institute Of Science Benzothiophene carboxamide compounds, composition and applications thereof
FR2963006B1 (fr) 2010-07-21 2013-03-15 Sanofi Aventis Procede de preparation de derives de nitro-benzofurane
FR2967067A1 (fr) 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
HUP1100165A2 (en) 2011-03-29 2012-12-28 Sanofi Sa Process for preparation of dronedarone by n-butylation
HUP1100167A2 (en) 2011-03-29 2012-11-28 Sanofi Sa Process for preparation of dronedarone by mesylation
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2983198B1 (fr) 2011-11-29 2013-11-15 Sanofi Sa Procede de preparation de derives de 5-amino-benzoyl-benzofurane
EP2617718A1 (en) 2012-01-20 2013-07-24 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
WO2013121235A2 (en) 2012-02-13 2013-08-22 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
WO2013121234A1 (en) 2012-02-14 2013-08-22 Sanofi Process for the preparation of dronedarone by oxidation of a sulphenyl group
WO2013124745A1 (en) 2012-02-22 2013-08-29 Sanofi Process for preparation of dronedarone by oxidation of a hydroxyl group
US9238636B2 (en) 2012-05-31 2016-01-19 Sanofi Process for preparation of dronedarone by Grignard reaction
CN105315245B (zh) * 2014-06-16 2018-10-12 华润赛科药业有限责任公司 苯并呋喃类衍生物、其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3248401A (en) * 1966-04-26 Diethylaminoe hoxybenzoyl benzofurans
GB1345872A (en) * 1970-09-03 1974-02-06 Wyeth John & Brother Ltd Amino-and acylamino-pyridine and hydropyridine derivatives
US4806663A (en) * 1987-04-06 1989-02-21 The University Of Tennessee Research Corporation Certain 3-substituted 2-alkyl benzofuran derivatives
US4851554A (en) 1987-04-06 1989-07-25 University Of Tennessee Research Corporation Certain 3-substituted 2-alkyl benzofuran derivatives
US4831054A (en) * 1988-04-18 1989-05-16 Taro Pharmaceuticals, Ltd. 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia
AT391316B (de) * 1988-09-15 1990-09-25 Ebewe Arzneimittel Neue thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5364880A (en) * 1993-06-16 1994-11-15 Advanced Therapies, Inc. Compound for treatment of cardiac arrhythmia, synthesis, and methods of use
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5523309A (en) * 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
CA2217373A1 (en) * 1996-10-10 1998-04-10 Michael John Martin Benzo¬b|thiophene compounds, intermediates, formulations, and methods

Also Published As

Publication number Publication date
NO20030800L (no) 2003-04-23
TWI290920B (en) 2007-12-11
NO20030800D0 (no) 2003-02-20
BR0113425A (pt) 2003-07-15
KR100911280B1 (ko) 2009-08-11
EA200300062A1 (ru) 2003-08-28
AU8414901A (en) 2002-03-04
IS6677A (is) 2003-01-13
IL153632A (en) 2007-07-24
JP5081363B2 (ja) 2012-11-28
IS2821B (is) 2013-02-15
JP2012097100A (ja) 2012-05-24
CZ304003B6 (cs) 2013-08-14
AR032892A1 (es) 2003-12-03
PL219848B1 (pl) 2015-07-31
NZ523446A (en) 2004-12-24
YU12903A (sh) 2006-05-25
US6949583B2 (en) 2005-09-27
JP2004506727A (ja) 2004-03-04
BG107527A (bg) 2003-10-31
PL362119A1 (en) 2004-10-18
FR2813306B1 (fr) 2005-10-21
US20030225100A1 (en) 2003-12-04
DK1315709T3 (da) 2010-09-20
EP1315709A1 (fr) 2003-06-04
WO2002016339A1 (fr) 2002-02-28
DE60142240D1 (de) 2010-07-08
SI1315709T1 (sl) 2010-09-30
ES2346291T3 (es) 2010-10-14
ATE469138T1 (de) 2010-06-15
MEP23008A (en) 2010-06-10
HK1053113A1 (en) 2003-10-10
BR0113425B1 (pt) 2014-02-25
CY1110738T1 (el) 2015-06-10
MXPA03001463A (es) 2004-05-04
SK288126B6 (sk) 2013-10-02
ZA200300744B (en) 2004-02-05
CZ2003521A3 (cs) 2003-05-14
HU229456B1 (en) 2013-12-30
HUP0302968A2 (hu) 2003-12-29
ME00106B (me) 2010-10-10
OA12359A (fr) 2006-05-16
EA006237B1 (ru) 2005-10-27
RS51603B (sr) 2011-08-31
EP1315709B1 (fr) 2010-05-26
CA2415847A1 (fr) 2002-02-28
HUP0302968A3 (en) 2005-02-28
JP5603849B2 (ja) 2014-10-08
NO328138B1 (no) 2009-12-14
BG66240B1 (bg) 2012-08-31
CA2415847C (fr) 2011-09-27
PT1315709E (pt) 2010-07-29
AU2001284149B2 (en) 2006-09-21
CN1471521A (zh) 2004-01-28
IL153632A0 (en) 2003-07-06
SK2162003A3 (en) 2003-08-05
FR2813306A1 (fr) 2002-03-01
KR20030023767A (ko) 2003-03-19
MA26943A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
CN1246315C (zh) 氨基烷基苯甲酰基－苯并呋喃或苯并噻吩类，它们的制备方法与含有它们的组合物
CN1146540C (zh) 具有镇痛作用的新化合物及其用途
CN1127487C (zh) 2,3－二氮杂萘酮及其用途和含2，3－二氮杂萘酮的药物
CN1045206C (zh) 一种环酰胺衍生物的制备方法
CN1242983C (zh) 苯氧基乙酸衍生物和含有该衍生物的医药组合物
CN1703403A (zh) 趋代谢的谷氨酸盐受体拮抗剂
CN1113236A (zh) 非肽基速激肽受体拮抗剂
CN1077954A (zh) 新的苯并吡喃衍生物
CN1906180A (zh) 新的长效β－2－激动剂及其作为药物的用途
CN1458921A (zh) N－芳基邻氨基苯甲酸和它们的衍生物的制备方法
CN1390193A (zh) 具有药学性质的新的二羧酸衍生物
CN1030252C (zh) 四氢苯并咪唑衍生物的制备方法
CN1268133A (zh) 含有稠合环取代基的作为nos抑制剂的2－氨基吡啶
CN1111622A (zh) 丙烯酸衍生物
CN1471520A (zh) 氨基烷氧基苯甲酰基-苯并呋喃类或苯并噻吩类,它们的制备方法以及含有它们的组合物
CN1250542C (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺
CN87100978A (zh) 新的二氢苯并呋喃—和苯并二氢吡喃—羧酰胺衍生物及其制备方法以及作为精神抑制药的应用
CN1084169A (zh) 新的苯基吡咯衍生物及其制备方法和用途
CN1281585C (zh) 具有稠环基团的环二胺化合物
CN1044651A (zh) 酰基苯酚衍生物
CN1100425A (zh) 噻唑并嘧啶衍生物
CN88102538A (zh) 新的双环化合物、其制备方法以及含这类化合物的药物组合物
CN1043706A (zh) 4，5，6，7-四氢化苯并咪唑衍生物制备方法
CN1273463C (zh) (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物
CN1835926A (zh) 非肽类取代螺苯并氮杂䓬衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SANOFI - AVENTIS

Free format text: FORMER OWNER: ST. SANOFI - SYNTHELABO CORPORATION

Effective date: 20050708

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20050708

Address after: France

Applicant after: Sanofi-Aventis

Address before: France

Applicant before: Sanofi-Synthelabo

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060322

Termination date: 20170821

CF01 Termination of patent right due to non-payment of annual fee